• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

精神分裂症患者的死亡率与躯体共病的关系。一项全国性匹配队列研究。

Mortality and the relationship of somatic comorbidities to mortality in schizophrenia. A nationwide matched-cohort study.

机构信息

Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary.

Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary.

出版信息

Eur Psychiatry. 2017 Sep;45:97-103. doi: 10.1016/j.eurpsy.2017.05.022. Epub 2017 Jun 12.

DOI:10.1016/j.eurpsy.2017.05.022
PMID:28753464
Abstract

AIM

We conducted a matched-cohort study to assess mortality in schizophrenia and the relationship of mortality with comorbid somatic conditions and suicide attempts.

METHOD

A full-population register-based prospective matched-cohort study was performed including all eligible patients with schizophrenia in Hungary between 01/01/2005 and 31/12/2013. Control subjects were individually matched to patients with schizophrenia at a 5:1 ratio. The principal outcome measure was death due to any reason. A non-parametric approach was used for descriptive statistical purposes, the Kaplan-Meier model for survival analysis, and the Cox proportional-hazards regression model for inferential statistics.

RESULTS

Patients with schizophrenia (n=65,169) had substantially higher risk of all-cause mortality than the control subjects (n=325,435) (RR=2.4; P<0.0001). Comorbidities and suicide attempts were associated with significantly increased mortality in both groups. As compared to the controls, 20-year old males with schizophrenia had a shorter life expectancy by 11.5years, and females by 13.7years; the analogous numbers for 45-year old schizophrenics were 8.1 and 9.6years, respectively.

CONCLUSIONS

A significant mortality gap - mainly associated with somatic comorbidities - was detected between patients with schizophrenia and individually matched controls. Improved medical training to address the disparity in mortality, and many other factors including lack of resources, access to and model of medical care, lifestyle, medication side effects, smoking, stigma, need for early intervention and adequate health care organization could help to better address the physical health needs of patients with schizophrenia.

摘要

目的

我们进行了一项匹配队列研究,以评估精神分裂症患者的死亡率,以及死亡率与合并躯体疾病和自杀企图的关系。

方法

这是一项基于人群的全队列注册前瞻性匹配队列研究,纳入了 2005 年 1 月 1 日至 2013 年 12 月 31 日期间匈牙利所有符合条件的精神分裂症患者。以 5:1 的比例对患者进行个体匹配。主要结局指标为任何原因导致的死亡。采用非参数方法进行描述性统计分析,采用 Kaplan-Meier 模型进行生存分析,采用 Cox 比例风险回归模型进行推断统计分析。

结果

精神分裂症患者(n=65169)的全因死亡率明显高于对照组(n=325435)(RR=2.4;P<0.0001)。合并症和自杀企图与两组的死亡率显著增加相关。与对照组相比,20 岁的男性精神分裂症患者预期寿命缩短了 11.5 年,女性缩短了 13.7 年;45 岁的精神分裂症患者的相应数字分别为 8.1 年和 9.6 年。

结论

在精神分裂症患者和个体匹配的对照组之间,发现了显著的死亡率差距,主要与躯体合并症有关。改善医学培训以解决死亡率差距,以及许多其他因素,包括缺乏资源、获得和医疗保健模式、生活方式、药物副作用、吸烟、耻辱感、需要早期干预和充分的医疗保健组织,可能有助于更好地满足精神分裂症患者的身体健康需求。

相似文献

1
Mortality and the relationship of somatic comorbidities to mortality in schizophrenia. A nationwide matched-cohort study.精神分裂症患者的死亡率与躯体共病的关系。一项全国性匹配队列研究。
Eur Psychiatry. 2017 Sep;45:97-103. doi: 10.1016/j.eurpsy.2017.05.022. Epub 2017 Jun 12.
2
Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia.全国精神分裂症自杀患者队列中药物治疗与自杀、自杀未遂及死亡风险之间的关联
Pharmacoepidemiol Drug Saf. 2008 Jul;17(7):686-96. doi: 10.1002/pds.1579.
3
Completed and attempted suicides among 18,154 subjects with schizophrenia included in a large simple trial.一项大型简易试验纳入的18154例精神分裂症患者中的自杀既遂和自杀未遂情况。
J Clin Psychiatry. 2014 Mar;75(3):e184-90. doi: 10.4088/JCP.13m08563.
4
Survival analysis of the use of first and second generation antipsychotics among patients suffering schizophrenia: A nationwide population-based cohort study.精神分裂症患者使用第一代和第二代抗精神病药物的生存分析:一项基于全国人口的队列研究。
Schizophr Res. 2015 Dec;169(1-3):406-411. doi: 10.1016/j.schres.2015.10.005. Epub 2015 Oct 23.
5
Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: to switch or to combine? A nationwide study in Hungary.抗精神病药单药治疗与联合治疗精神分裂症的真实世界疗效:转换还是联合?匈牙利全国性研究。
Schizophr Res. 2014 Jan;152(1):246-54. doi: 10.1016/j.schres.2013.10.034. Epub 2013 Nov 22.
6
Type-2 diabetes mellitus in schizophrenia: increased prevalence and major risk factor of excess mortality in a naturalistic 7-year follow-up.精神分裂症中的 2 型糖尿病:在自然随访 7 年中,患病率增加和导致超额死亡率的主要危险因素。
Eur Psychiatry. 2012 Jan;27(1):33-42. doi: 10.1016/j.eurpsy.2011.02.009. Epub 2011 May 13.
7
[Mortality among chronic schizophrenic patients: a prospective 14-year follow-up study of 150 schizophrenic patients].[慢性精神分裂症患者的死亡率:对150例精神分裂症患者进行的为期14年的前瞻性随访研究]
Encephale. 2008 Jan;34(1):54-60. doi: 10.1016/j.encep.2007.07.005. Epub 2007 Sep 5.
8
All-cause mortality and medication risk factors in schizophrenia: a prospective cohort study.精神分裂症全因死亡率和药物相关风险因素:一项前瞻性队列研究。
J Clin Psychopharmacol. 2012 Feb;32(1):31-5. doi: 10.1097/JCP.0b013e31823f3c43.
9
[Drawing up guidelines for the attendance of physical health of patients with severe mental illness].[制定重症精神疾病患者身体健康检查指南]
Encephale. 2009 Sep;35(4):330-9. doi: 10.1016/j.encep.2008.10.014. Epub 2009 Jul 9.
10
Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP).赛乐特(Sertindole)与利培酮治疗精神分裂症的安全性比较:赛乐特队列前瞻性研究(SCoP)的主要结果。
Acta Psychiatr Scand. 2010 Nov;122(5):345-55. doi: 10.1111/j.1600-0447.2010.01563.x.

引用本文的文献

1
What is behind the 17-year life expectancy gap between individuals with schizophrenia and the general population?精神分裂症患者与普通人群之间17年的预期寿命差距背后的原因是什么?
Schizophrenia (Heidelb). 2025 Aug 29;11(1):117. doi: 10.1038/s41537-025-00667-1.
2
Mortality rate in patients in a long-term psychiatric care facility in Johannesburg.约翰内斯堡一家长期精神病护理机构中患者的死亡率。
S Afr J Psychiatr. 2024 Nov 27;30:2329. doi: 10.4102/sajpsychiatry.v30i0.2329. eCollection 2024.
3
Implementation of the healthy heart tool- an algorithm with potential cardiometabolic health benefits in persons with severe mental illness.
健康心脏工具的实施——一种对重度精神疾病患者具有潜在心脏代谢健康益处的算法。
BMC Psychiatry. 2025 Feb 25;25(1):172. doi: 10.1186/s12888-025-06578-w.
4
Clinical pharmacist recommendations in daily interdisciplinary ward rounds at a psychiatric hospital: a retrospective pre-post study on drug-related problems focused in somatic comorbidities.一家精神病医院日常跨学科病房查房中临床药师的建议:一项聚焦躯体合并症的药物相关问题的前后回顾性研究。
Front Psychiatry. 2024 Dec 20;15:1473832. doi: 10.3389/fpsyt.2024.1473832. eCollection 2024.
5
Mortality in patients with major depressive disorder: A nationwide population-based cohort study with 11-year follow-up.患有重度抑郁症患者的死亡率:一项全国范围内基于人群的队列研究,随访 11 年。
Eur Psychiatry. 2024 Sep 30;67(1):e63. doi: 10.1192/j.eurpsy.2024.1771.
6
Comparative effectiveness of clozapine and non-clozapine atypical antipsychotics provided by the Brazilian National Health System in adults with schizophrenia.巴西国家卫生系统提供的氯氮平和非氯氮平非典型抗精神病药物对成人精神分裂症患者的比较疗效
Front Psychiatry. 2024 Jun 19;15:1421501. doi: 10.3389/fpsyt.2024.1421501. eCollection 2024.
7
Integrating Electronic Health Records and Polygenic Risk to Identify Genetically Unrelated Comorbidities of Schizophrenia That May Be Modifiable.整合电子健康记录和多基因风险以识别精神分裂症可能可改变的非遗传共病。
Biol Psychiatry Glob Open Sci. 2024 Feb 28;4(3):100297. doi: 10.1016/j.bpsgos.2024.100297. eCollection 2024 May.
8
Life expectancy and years of potential life lost in people with mental disorders: a systematic review and meta-analysis.精神障碍患者的预期寿命和潜在寿命损失年数:一项系统评价和荟萃分析。
EClinicalMedicine. 2023 Oct 31;65:102294. doi: 10.1016/j.eclinm.2023.102294. eCollection 2023 Nov.
9
Monitoring the Effectiveness of Treatment in Women with Schizophrenia: New Specialized Cooperative Approaches.监测精神分裂症女性患者的治疗效果:新的专业合作方法。
Brain Sci. 2023 Aug 25;13(9):1238. doi: 10.3390/brainsci13091238.
10
Psychiatric polygenic risk as a predictor of COVID-19 risk and severity: insight into the genetic overlap between schizophrenia and COVID-19.精神疾病多基因风险作为 COVID-19 风险和严重程度的预测因子:精神分裂症和 COVID-19 之间遗传重叠的深入了解。
Transl Psychiatry. 2023 Jun 6;13(1):189. doi: 10.1038/s41398-023-02482-7.